Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* Male, age below 6 years of age at the time of signing informed consent~* Diagnosis of severe haemophilia A (FVIII activity level 1%) based on medical records or central laboratory results~* No prior use of purified clotting factor products (5 previous exposures to blood components is acceptable)~Exclusion Criteria:~* Any history of FVIII inhibitor (defined by medical records) - Known or suspected hypersensitivity to trial product or related products~* Previous participation in this trial. Participation is defined as first dose administered of trial product~* Receipt of any investigational medicinal product within 30 days before screening~* Congenital or acquired coagulation disorder other than haemophilia A~* Any chronic disorder or severe disease which, in the opinion of the Investigator, might jeopardise the patient's safety or compliance with the protocol~* Patient's parent(s')/legally acceptable representative (LAR(s')) mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation

- Gender: MALE
- Minimum Age: 0 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- 50 EDs (exposure days) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).